Mabpharm Limited (HK:2181) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Mabpharm Limited has received approval from the Indonesian National Agency of Drug and Food Control for their core product, CMAB008 (infliximab for injection), to treat several conditions including ulcerative colitis and rheumatoid arthritis. This biosimilar medicine, originating from China, offers a more economical option for patients due to its inclusion in China’s basic medical insurance program. Investors may find this approval promising as it expands Mabpharm’s market reach and potential revenue streams.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.